Advances in Escherichia coli production of therapeutic proteins.
Escherichia coli offers a means for the rapid and economical production of recombinant proteins. These advantages, coupled with a wealth of biochemical and genetic knowledge, have enabled the production of such economically sensitive products as insulin and bovine growth hormone. Although significant progress has been made in transcription, translation and secretion, one of the major challenges is obtaining the product in a soluble and bioactive form. Recent progress in oxidative cytoplasmic folding and cell-free protein synthesis offers attractive alternatives to standard expression methods.
Swartz
J R
JR
Department of Chemical Engineering, Stanford University, Stanford, CA 94305-5025, USA. swartz@chemeng.stanford.edu
D002474:Cell-Free System; D003593:Cytoplasm / Q000737:chemistry; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism; D015964:Gene Expression Regulation, Bacterial; D005822:Genetic Vectors / Q000235:genetics; D019897:Periplasm / Q000737:chemistry; D011401:Promoter Regions, Genetic / Q000235:genetics; D014176:Protein Biosynthesis; D017510:Protein Folding; D020871:RNA Stability; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000627:therapeutic use
D011994:Recombinant Proteins